Investors & Media
Company Overview
View All
LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.

Featured Release
LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patients with Type 1 Diabetes
April 11, 2023 - The collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Read More